Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on June 11, 2026

Jun. 11, 2026

BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026

Indeterminate GlobeNewswire

Jun. 11, 2026

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Indeterminate GlobeNewswire

Jun. 11, 2026

Bereaved Mothers Give a Gift to Every Grieving Father: The “All Fathers Day” Free Grief Support Bundle. A Documentary Film. A Live Father’s Day Support Group. Free Online Courses. A Dedicated Community. All Free. All at AllFathersDay.com

Indeterminate GlobeNewswire

Jun. 11, 2026

Neion Bio Raises Oversubscribed $23 Million Series A to Advance Biologics Manufacturing Platform and Expand Pipeline

Indeterminate GlobeNewswire

Jun. 11, 2026

BrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team’s Return

Indeterminate GlobeNewswire

Jun. 11, 2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

Indeterminate GlobeNewswire

Jun. 11, 2026

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Indeterminate GlobeNewswire

Jun. 11, 2026

Verano Completes 1-for-5 Reverse Stock Split, Advancing the Company’s Path Towards Prospective U.S. Stock Exchange Listing

Indeterminate GlobeNewswire

Jun. 11, 2026

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Indeterminate GlobeNewswire

Jun. 11, 2026

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Indeterminate GlobeNewswire

Jun. 11, 2026

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

Indeterminate GlobeNewswire

Jun. 11, 2026

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Indeterminate GlobeNewswire

Jun. 11, 2026

Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia

Indeterminate GlobeNewswire

Jun. 11, 2026

Pharvaris Announces Annual General Meeting of Shareholders

Indeterminate GlobeNewswire

Jun. 11, 2026

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

Indeterminate GlobeNewswire

Jun. 11, 2026

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease

Indeterminate GlobeNewswire

Jun. 11, 2026

Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline

Indeterminate GlobeNewswire

Jun. 11, 2026

Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

Indeterminate GlobeNewswire

Jun. 11, 2026

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Indeterminate GlobeNewswire

Jun. 11, 2026

Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026

Indeterminate GlobeNewswire